middle.news
How Race Oncology’s $2.8M R&D Refund Could Transform Cancer Treatment Trials
9:06am on Thursday 27th of November, 2025 AEDT
•
Healthcare
Read Story
How Race Oncology’s $2.8M R&D Refund Could Transform Cancer Treatment Trials
9:06am on Thursday 27th of November, 2025 AEDT
Key Points
Received $2.8 million R&D tax refund for FY2025
Additional overseas R&D refund anticipated in early 2026
Government guarantee for up to $20 million in R&D rebates over three years
Funds to support clinical trials of lead asset RC220 in multiple cancer indications
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE